Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Gottesman Website

Michael M. Gottesman, M.D.

Selected Publications

1)  Fung KL, Pan J, Ohnuma S, Lund PE, Pixley JN, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM.
MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer.
Cancer Res. 74: 598-608, 2014.
2)  Lavi O, Greene JM, Levy D, Gottesman MM.
Simplifying the complexity of resistance heterogeneity in metastasis.
Trends Mol Med. 20: 129-136, 2014.
3)  Greene J, Lavi O, Gottesman MM, Levy D.
The impact of cell density and mutations in a model of multidrug resistance in solid tumors.
Bull. Math. Biol. 76: 627-53, 2014.
4)  Bakhsheshian J, Wei BR, Chang KE, Shukla S, Ambudkar SV, Simpson RM, Gottesman MM, Hall MD.
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
Proc. Natl. Acad. Sci. U.S.A. 110: 20801-6, 2013.
5)  Pouliot LM, Shen DW, Suzuki T, Hall MD, Gottesman MM.
Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells.
Exp. Cell Res. 319: 566-74, 2013.
6)  Kannan P, Pike VW, Halldin C, Langer O, Gottesman MM, Innis RB, Hall MD.
Factors that limit positron emission tomography imaging of p-glycoprotein density at the blood-brain barrier.
Mol. Pharm. 10: 2222-9, 2013.
7)  Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet J, Kossenkov AV, Wilkerson J, Showe LC, Gottesman MM, Collie NL, Bates SE.
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with a MEK inhibitor.
Blood. [Epub ahead of print], 2013.
8)  Jaeger AA, Das CK, Morgan NY, Pursley RH, McQueen PG, Hall MD, Pohida TJ, Gottesman MM.
Microfabricated polymeric vessel mimetics for 3-D cancer cell culture.
Biomaterials. 34: 8301-13, 2013.
9)  Patel C, Stenke L, Varma S, Lindberg ML, Björkholm M, Sjöberg J, Viktorsson K, Lewensohn R, Landgren O, Gottesman MM, Gillet JP.
Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity.
Cancer. 2013.
10)  Xue X, Hall MD, Zhang Q, Wang PC, Gottesman MM, Liang XJ.
Nanoscale Drug Delivery Platforms Overcome Platinum-Based Resistance in Cancer Cells Due to Abnormal Membrane Protein Trafficking.
ACS Nano. 2013.
Click Here to View Expanded Bibliography.

This page was last updated on 4/1/2014.